A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC# 91485) versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
This randomized phase II/III trial studies how well paclitaxel, carboplatin, and metformin
hydrochloride works and compares it to paclitaxel, carboplatin, and placebo in treating
patients with stage III, IV, or recurrent endometrial cancer. Drugs used in chemotherapy,
such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor
cells, either by killing the cells or by stopping them from dividing. Metformin
hydrochloride may help paclitaxel and carboplatin work better by making cancer cells more
sensitive to the drugs. It is not yet known whether paclitaxel and carboplatin is more
effective with or without metformin hydrochloride in treating endometrial cancer.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.